Fast-track pathway for giant cell arteritis: Improved visual outcomes and reduced healthcare costs

by Loïc Duron, Thibaud Chazal, Thomas Sene, Julien Savatovsky, Augustin Lecler

Background

Giant cell arteritis (GCA) is the leading vasculitis threatening vision in adults aged ≥ 50 years; permanent vision loss may occur within the first few days after symptom onset. We assessed the impact of a fast-track pathway (FTP) for early diagnosis and treatment of giant cell arteritis in terms of hospitalization patterns and cost-effectiveness.

Methods

We conducted a retrospective, single-center medico-economic study of consecutive patients referred to a neuro-ophthalmology tertiary center between Nov 1, 2016, and Dec 31, 2022. GCA was defined by ≥ 3 American College of Rheumatology criteria plus a positive temporal-artery biopsy or vascular imaging. An FTP—24/7 access to internal medicine specialists, priority magnetic-resonance imaging, and protocol-driven corticosteroid initiation—was launched on Nov 1, 2018. Demographic, clinical, biological, care-pathway, and cost data were compared before (pre-FTP) and after (post-FTP) implementation. Continuous variables were analyzed with two-sample t tests or Wilcoxon rank–sum tests; categorical variables with χ² or Fisher’s exact test.

Findings

We included 135 patients (mean age 76 ± 8 years, 61% women): 23 pre-FTP and 112 post-FTP. Baseline characteristics were similar between groups. Compared with the pre-FTP period, the FTP reduced full hospitalizations (62% [69/112] vs 96% [22/23]; p  Interpretation

A dedicated fast-track pathway for suspected GCA enables prompt, largely ambulatory care, halves unnecessary full hospitalizations, speeds treatment initiation, improves visual prognosis, and lowers overall expenditure. These findings support wider adoption of imaging-driven FTPs to mitigate the growing clinical and economic burden of GCA.